Retinopathy of prematurity: Is genetic predisposition an important risk factor?

Expert Review of Ophthalmology

Volumn 2, Issue 2, 2007, Pages 275-283

  Kwinta, Przemko ^a   Pietrzyk, jacek J ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

familial exudative vitreoretinopathy; gene polymorphism; insulin like growth factor 1; interleukin 10; preterm newborns; retinopathy of prematurity; transforming growth factor; tumor necrosis factor; vascular endothelial growth factor; very low birth weight newborns

Indexed keywords

EID: 84858248578     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2.2.275     Document Type: Article

References (82)

1. Haines JL, Fielder A, Baker H, Wilkinson AR. UK population based study of severe retinopathy of prematurity: screening, treatment, and outcome. Arch. Dis. Child. Fetal Neonatal Ed. 90, 240–244 (2005).
2. Kaiser RS, Trese MT, Williams GA, Cox MS. Adult retinopathy of prematurity: outcomes of rhegmatogenous retinal detachments and retinal tears. Ophthalmology 108, 1647–1653 (2001).
3. Gilbert C, Fielder A, Gordillo L et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 115, e518 –e525 (2005).
4. Tompkins C. A sudden rise in the prevalence of retinopathy of prematurity blindness? Pediatrics 108, 526–526 (2001).
5. Palmer EA. Implications of the natural course of retinopathy of prematurity. Pediatrics 111, 885–886 (2003).
6. Holmstrom GE, Broberger U, Thomassen P. Neonatal risk factors for retinopathy of prematurity – a population- based study. Acta Ophthalmol. Scand. 76, 204–207 (1998).
7. Karna P, Muttineni J, Angell L, Karmaus W. Retinopathy of prematurity and risk factors: a prospective cohort study. BMC Pediatr. 5, 18 (2005).
8. Wheatley CM, Dickinson JL, Mackey DA, Craig JE, Sale MM. Retinopathy of prematurity: recent advances of our understanding. Arch. Dis. Child Fetal Neonatal Ed. 87, F78 –F82 (2002).
9. Schaffer DB, Palmer EA, Plotsky DF et al. Prognostic factors in the natural course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 100, 230–237 (1993).
10. Hutchinson AK, O’Neil JW, Morgan EN, Cervenak MA, Saunders RA. Retinopathy of prematurity in infants with birth weights greater than 1250 grams. J. AAPOS 7, 190–194 (2003).
11. Saunders RA, Donahue ML, Christmann LM et al. Racial variation in retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch. Ophthalmol. 115, 604–608 (1997).
12. Arnold RW, Kesler K, Avila E. Susceptibility to retinopathy of prematurity in Alaskan Natives. J. Pediatr. Ophthalmol. Strabismus 31, 192–194 (1994).
13. Leo SW, Cheong PY. Incidence of retinopathy of prematurity in Singapore. Singapore Med. J. 38, 54–57 (1997).
14. Bizzarro MJ, Hussain N, Jonsson B et al. Genetic susceptibility to retinopathy of prematurity. Pediatrics 118, 1858–1863 (2006).
15. Fukai N, Eklund L, Marneros AG et al. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J. 21, 1535–1544 (2002).
16. Sertie AL, Sossi V, Camargo AA, Zatz M, Brahe C, Passos-Bueno MR. Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure (Knobloch syndrome). Hum. Mol. Genet. 9, 2051–2058 (2000).
17. Rogers MS, D’Amato RJ. The effect of genetic diversity on angiogenesis. Exp. Cell Res. 312, 561–574 (2006).
18. Omoto S, Hayashi T, Kitahara K, Takeuchi T, Ueoka Y. Autosomal dominant familial exudative vitreoretinopathy in two Japanese families with FZD4 mutations (H69Y and C181R). Ophthalmic Genet. 25, 81–90 (2004).
19. Downey LM, Keen TJ, Roberts E, Mansfield DC, Bamashmus M, Inglehearn CF. A new locus for autosomal dominant familial exudative vitreoretinopathy maps to chromosome 11p12–13. Am. J. Hum. Genet. 68, 778–781 (2001).
20. Drenser KA, Dailey W, Capone A, Trese MT. Genetic evaluation to establish the diagnosis of X-linked familial exudative vitreoretinopathy. Ophthalmic Genet. 27, 75–78 (2006).
21. Riveiro-Alvarez R, Trujillo-Tiebas MJ, Gimenez-Pardo A et al. Genotype–phenotype variations in five Spanish families with Norrie disease or X-linked FEVR. Mol. Vis. 11, 705–712 (2005).
22. de Crecchio G, Simonelli F, Nunziata G et al. Autosomal recessive familial exudative vitreoretinopathy: evidence for genetic heterogeneity. Clin. Genet. 54, 315–320 (1998).
23. Toomes C, Bottomley HM, Jackson RM et al. Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am. J. Hum. Genet. 74, 721–730 (2004).
24. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis: a look outside the nucleus. Science 287, 1606–1609 (2000).
25. Jiao X, Ventruto V, Trese MT, Shastry BS, Hejtmancik JF. Autosomal recessive familial exudative vitreoretinopathy is associated with mutations in LRP5. Am. J. Hum. Genet. 75, 878–884 (2004).
26. Downey LM, Bottomley HM, Sheridan E et al. Reduced bone mineral density and hyaloid vasculature remnants in a consanguineous recessive FEVR family with a mutation in LRP5. Br. J. Ophthalmol. 90, 1163–1167 (2006).
27. MacDonald ML, Goldberg YP, Macfarlane J, Samuels ME, Trese MT, Shastry BS. Genetic variants of frizzled-4 gene in familial exudative vitreoretinopathy and advanced retinopathy of prematurity. Clin. Genet. 67, 363–366 (2005).
28. Sims KB, Lebo R V, Benson G et al. The Norrie disease gene maps to a 150 kb region on chromosome Xp11.3. Hum. Mol. Genet. 1, 82–83 (1992).
29. Shastry BS, Pendergast SD, Hartzer MK, Liu X, Trese MT. Identification of missense mutations in the Norrie disease gene associated with advanced retinopathy of prematurity. Arch. Ophthalmol. 115, 651–655 (1997).
30. Buffenn AN, Bernstein SL, Hutcheson KA. Identification of a new Norrie disease gene mutation in an African-American infant with advanced retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 40, S565 (1999).
31. Haider MZ, Devarajan LV, Al Essa M et al. Retinopathy of prematurity: mutations in the Norrie disease gene and the risk of progression to advanced stages. Pediatr. Int. 43, 120–123 (2001).
32. Haider MZ, Devarajan LV, Al Essa M, Kumar H. A C597 – a polymorphism in the Norrie disease gene is associated with advanced retinopathy of prematurity in premature Kuwaiti infants. J. Biomed. Sci. 9, 365–370 (2002).
33. Hiraoka M, Berinstein DM, Trese MT, Shastry BS. Insertion and deletion mutations in the dinucleotide repeat region of the Norrie disease gene in patients with advanced retinopathy of prematurity. J. Hum. Genet. 46, 178–181 (2001).
34. Talks SJ, Ebenezer N, Hykin P et al. De novo mutations in the 5' regulatory region of the Norrie disease gene in retinopathy of prematurity. J. Med. Genet. 38, E46 (2001).
35. Hutcheson KA, Paluru PC, Bernstein SL et al. Norrie disease gene sequence variants in an ethnically diverse population with retinopathy of prematurity. Mol. Vis. 11, 501–508 (2005).
36. Dickinson JL, Sale MM, Passmore A et al. Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity. Clin. Experiment. Ophthalmol. 34, 682–688 (2006).
37. Nallathambi J, Shukla D, Rajendran A, Namperumalsamy P, Muthulakshmi R, Sundaresan P. Identification of novel FZD4 mutations in Indian patients with familial exudative vitreoretinopathy. Mol. Vis. 12, 1086–1092 (2006).
38. Qin M, Hayashi H, Oshima K, Tahira T, Hayashi K, Kondo H. Complexity of the genotype–phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and/or FZD4 genes. Hum. Mutat. 26, 104–112 (2005).
39. Yoshida S, Arita R, Yoshida A et al. Novel mutation in FZD4 gene in a Japanese pedigree with familial exudative vitreoretinopathy. Am. J. Ophthalmol. 138, 670–671 (2004).
40. Toomes C, Downey LM, Bottomley HM et al. Identification of a fourth locus (EVR4) for familial exudative vitreoretinopathy (FEVR). Mol. Vis. 10, 37–42 (2004).
41. Helminger G, Endo M, Ferrara N, Hlatky L, Jain RK. Formation of endothelial cell networks. Nature 405, 139–141 (2000).
42. Wei MH, Popescu NC, Lerman MI, Merrill MJ, Zimonjic DB. Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum. Genet. 97, 794–797 (1996).
43. Makino Y, Cao R, Svensson K et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414, 550–554 (2001).
44. Pierce EA, Folez ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch. Ophthalmol. 114, 1219–1228 (1996).
45. Leske DA, Wu J, Mookadam M et al. The relationship of retinal VEGF and retinal IGF-1 mRNA with neovascularization in an acidosis-induced model of retinopathy of prematurity. Curr. Eye Res. 31, 163–169 (2006).
46. Leske DA, Wu J, Fautsch MP et al. The role of VEGF and IGF-1 in a hypercarbic oxygen-induced retinopathy rat model of ROP. Mol. Vis. 10, 43–50 (2004).
47. Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS. Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Exp. Eye Res. 79, 623–630 (2004).
48. McLeod DS, Taomoto M, Cao J, Zhu Z, Witte L, Lutty GA. Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 43, 474–482 (2002).
49. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26, 859–870 (2006).
50. Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113, 2002–2012 (2006).
51. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol. Clin. North Am. 19, 361–372 (2006).
52. Vannay A, Dunai G, Banyasz I et al. Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. Pediatr. Res. 57, 396–398 (2005).
53. Watson CJ, Webb NJ, Bottomley MJ, Brenchley P. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12, 1232–1235 (2000).
54. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res. 37, 443–448 (2000).
55. Awata T, Inoue K, Kurihara S et al. A common polymorphism in the 5´ untranslated region of the VEGF gene is associated with diabetic retinopathy in Type 2 diabetes. Diabetes 51, 1635–1639 (2002).
56. Awata T, Kurihara S, Takata N et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in Type 2 diabetes. Biochem. Biophys. Res. Commun. 333, 679–685 (2005).
57. Suganthalakshmi B, Anand R, Kim R et al. Association of VEGF and eNOS gene polymorphisms in Type 2 diabetic retinopathy. Mol. Vis. 12, 336–341 (2006).
58. Banyasz I, Bokodi G, Vannay A et al. Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity. Curr. Eye Res. 31, 685–690 (2006).
59. Cooke RW, Drury JA, Mountford R, Clark D. Genetic polymorphisms and retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 45, 1712–1715 (2004).
60. Kwinta P, Mitkowska Z, Tomasik T, Bik-Multanowski M, Pietrzyk JJ. Vascular endothelial growth factor gene polymorphisms and the risk of retinopathy of prematurity. Pediatr. Res. 56, 465–511 (2004).
61. Shastry BS, Qu X. Lack of association of the VEGF gene promoter (-634 G –>C and H460 C–>T) polymorphism and the risk of advanced retinopathy of prematurity. Graefes Arch. Clin. Exp. Ophthalmol. DOI: 10.1007/s00417-006-0480-6 (2006) (Epub ahead of print).
62. Sennlaub F, Chemtob S. VEGFR-1: a safe target for prophylaxis of retinopathy of prematurity? Pediatr. Res. 55, 1–2 (2004).
63. Kariyazono H, Ohno T, Khajoee V et al. Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr. Res. 56, 953–959 (2004).
64. Lofqvist C, Engstrom E, Sigurdsson J et al. Postnatal head growth deficit among premature infants parallels retinopathy of prematurity and insulin-like growth factor H1 deficit. Pediatrics 117, 1930–1938 (2006).
65. Hellstrom A, Engstrom E, Hard AL et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 112, 1016–1020 (2003).
66. Smith LE. IGF-1 and retinopathy of prematurity in the preterm infant. Biol. Neonate 88, 237–244 (2005).
67. ‘t Hart LM, Fritsche A, Rietveld I et al. Genetic factors and insulin secretion: gene variants in the IGF genes. Diabetes 53 (Suppl. 1), S26 –S30 (2004).
68. Al Zahrani A, Sandhu MS, Luben RN et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum. Mol. Genet. 15, 1–10 (2006).
69. Johnston LB, Dahlgren J, Leger J et al. Association between insulin-like growth factor I (IGF-I) polymorphisms, circulating IGF-I, and pre- and postnatal growth in two European small for gestational age populations. J. Clin. Endocrinol. Metab. 88, 4805–4810 (2003).
70. te Velde SJ, van Rossum EF, Voorhoeve PG et al. An IGF-I promoter polymorphism modifies the relationships between birth weight and risk factors for cardiovascular disease and diabetes at age 36. BMC Endocr. Disord. 5, 5 (2005).
71. Frayling TM, Hattersley AT, McCarthy A et al. A putative functional polymorphism in the IGF-I gene: association studies with Type 2 diabetes, adult height, glucose tolerance, and fetal growth in U.K. populations. Diabetes 51, 2313–2316 (2002).
72. Rietveld I, Ikram MK, Vingerling JR et al. An IGF-I gene polymorphism modifies the risk of diabetic retinopathy. Diabetes 55, 2387–2391 (2006).
73. Kwinta P, Bik-Multanowski M, Mitkowska Z, Tomasik T, Kobylarz J, Pietrzyk JJ. Retinopathy of prematurity: is genetic predisposition an important risk factor? Invest. Ophthalmol. Vis. Sci. (2006) (In press).
74. Balogh A, Derzbach L, Vannay A, Vasarhelyi B. Lack of association between insulin-like growth factor I receptor G(+3174)A polymorphism and retinopathy of prematurity. Graefes Arch. Clin. Exp. Ophthalmol. 244, 1035–1038 (2006).
75. Li B, Khanna A, Sharma V, Singh T, Suthanthiran M, August P. TGF-b1 DNA polymorphism, protein levels, and blood pressure. hypertension 33, 271–275 (1999).
76. Beranek M, Kankova K, Benes P et al. Polymorphism R25P in the gene encoding transforming growth factor-β (TGF- β1) is a newly identified risk factor for proliferative diabetic retinopathy. Am. J. Med. Genet. 109, 278–283 (2002).
77. Mazaheri S, Hajilooi M, Rafiei A. The G-308A promoter variant of the tumor necrosis factor-α gene is associated with migraine without aura. J. Neurol. 253 (12), 1589–1593 (2006).
78. Sykora J, Subrt I, Didek P et al. Cytokine tumor necrosis factor-α a promoter gene polymorphism at position -308 G–>A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn’s Disease. J. Pediatr. Gastroenterol. Nutr. 42, 479–487 (2006).
79. Li YF, Gauderman WJ, Avol E, Dubeau L, Gilliland FD. Associations of tumor necrosis factor G-308A with childhood asthma and wheezing. Am. J. Respir. Crit. Care Med. 173, 970–976 (2006).
80. Yanamandra K, Boggs P, Loggins J, Baier RJ. Interleukin-10 -1082 G/A polymorphism and risk of death or bronchopulmonary dysplasia in ventilated very low birth weight infants. Pediatr. Pulmonol. 39, 426–432 (2005).
81. Haider MZ, Devarajan LV, Al Essa M, Kumar H. Angiotensin-converting enzyme gene insertion/deletion polymorphism in Kuwaiti children with retinopathy of prematurity. Biol. Neonate 82, 84–88 (2002).
82. Csak K, Szabo V, Szabo A, Vannay A. Pathogenesis and genetic basis for retinopathy of prematurity. Front Biosci. 11, 908–920 (2006).